Your browser is no longer supported. Please, upgrade your browser.
Jasper Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own25.70% Shs Outstand12.50M Perf Week-30.02%
Market Cap318.96M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-19.99%
Income-4.30M PEG- EPS next Q- Inst Own57.10% Short Float- Perf Quarter15.59%
Sales- P/S- EPS this Y-986.70% Inst Trans298.97% Short Ratio0.04 Perf Half Y14.90%
Book/sh6.90 P/B1.67 EPS next Y- ROA-4.30% Target Price- Perf Year15.77%
Cash/sh0.01 P/C1063.21 EPS next 5Y- ROE-4.80% 52W Range7.11 - 18.88 Perf YTD14.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.14% Beta-
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin- 52W Low61.60% ATR2.55
Employees24 Current Ratio1.30 Sales Q/Q- Oper. Margin- RSI (14)50.34 Volatility14.83% 27.36%
OptionableNo Debt/Eq0.00 EPS Q/Q-4.00% Profit Margin- Rel Volume0.28 Prev Close13.25
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.69M Price11.49
Recom- SMA202.90% SMA508.88% SMA20013.01% Volume765,503 Change-13.28%
Oct-21-21Initiated William Blair Outperform
Oct-20-21Initiated BMO Capital Markets Outperform $19
Oct-13-21Initiated Oppenheimer Outperform $21
Oct-15-21 09:39PM  
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.